Login to Your Account



Allergan, Foamix advance acne drugs with contrasting results

By Michael Fitzhugh
Staff Writer

Monday, March 27, 2017

Positive data from dual phase III studies of oral sarecycline in moderate to severe acne poised originator Paratek Pharmaceuticals Inc. to earn a $5 million milestone payment from partner Allergan plc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription